These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 26909474)

  • 1. Precision medicine for advanced prostate cancer.
    Mullane SA; Van Allen EM
    Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
    Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
    Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for DNA repair-deficient prostate cancer.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions for precision oncology in prostate cancer.
    Mizuno K; Beltran H
    Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular tumor board prostate cancer].
    Seitz AK; Heck MM; Kamer MW; Grüllich C
    Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G; Ikeda S; Kurzrock R
    Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
    Fraser M; Berlin A; Bristow RG; van der Kwast T
    Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 10. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards precision oncology in advanced prostate cancer.
    Ku SY; Gleave ME; Beltran H
    Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.
    Hovelson DH; Tomlins SA
    Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Mar; 33(3):113-8. PubMed ID: 30866035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    Palmbos PL; Hussain MH
    Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
    Considine B; Petrylak DP
    Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.